CASI (CASI Pharmaceuticals, Inc. Ordinary Shares)
Insider Trading Activity
Every open-market purchase and sale reported by CASI officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2022-09-09 | Alexander A Zukiwski | EVP and Chief Medical Officer | A | — | — |
| 2022-09-08 | James Huang | Director | Buy | — | — |
| 2022-09-02 | James Huang | Director | Buy | — | — |
| 2022-08-26 | James Huang | Director | Buy | — | — |
| 2022-08-23 | James Huang | Director | Buy | — | — |
| 2022-06-17 | Wei-Wu He | Chairman and CEO | Buy | — | — |
| 2022-05-26 | James Huang | Director | A | — | — |
| 2022-05-26 | RAJESH C MD SHROTRIYA | Director | A | — | — |
| 2022-05-26 | Franklin Cary Salisbury jr | Director | A | — | — |
| 2022-05-26 | Yue Alexander Wu | Director | A | — | — |
| 2022-05-26 | Quan Zhou | Director | A | — | — |
| 2021-12-06 | Alexander A Zukiwski | Chief Medical Officer | A | — | — |
| 2021-11-19 | Wei-Wu He | Chairman and CEO | Buy | — | — |
| 2021-08-20 | Wei-Wu He | Chairman and CEO | Buy | — | — |
| 2021-07-26 | Larry Zhang | President | A | — | — |
| 2021-06-16 | James Huang | Director | A | — | — |
| 2021-06-16 | Quan Zhou | Director | A | — | — |
| 2021-06-16 | RAJESH C MD SHROTRIYA | Director | A | — | — |
| 2021-06-16 | Franklin Cary Salisbury jr | Director | A | — | — |
| 2021-06-16 | Yue Alexander Wu | Director | A | — | — |
| 2021-06-16 | Wei-Wu He | Chairman and CEO | A | — | — |
| 2021-03-30 | Wei-Wu He | Chairman and CEO | Buy | — | — |
| 2020-12-23 | Wei-Wu He | Chairman and CEO | G | — | — |
| 2020-12-18 | Weihao Xu | Chief Financial Officer | Buy | — | — |
| 2020-11-24 | Wei-Wu He | Chairman and CEO | Buy | — | — |
| 2020-07-24 | Larry Zhang | President | Buy | — | — |
| 2020-07-24 | Wei-Wu He | Chairman and CEO | Buy | — | — |
| 2020-06-18 | James Huang | Director | A | — | — |
| 2020-06-18 | Yue Alexander Wu | Director | A | — | — |
| 2020-06-18 | Franklin Cary Salisbury jr | Director | A | — | — |
| 2020-06-18 | Quan Zhou | Director | A | — | — |
| 2020-06-18 | RAJESH C MD SHROTRIYA | Director | A | — | — |
| 2020-05-21 | Wei-Wu He | Chairman and CEO | Buy | — | — |
| 2020-05-19 | Wei-Wu He | Chairman and CEO | Buy | — | — |
| 2020-03-30 | Wei-Wu He | Chairman and CEO | Buy | — | — |
| 2020-03-27 | Wei-Wu He | Chairman and CEO | Buy | — | — |
| 2020-03-19 | Wei-Wu He | Chairman and CEO | Buy | — | — |
| 2020-01-06 | Wealth Strategy Holding Ltd | 10%+ Owner | X | — | — |
| 2019-12-18 | Wei-Wu He | Chairman and CEO | X | — | — |
| 2019-12-17 | Alexander A Zukiwski | Chief Medical Officer | A | — | — |
| 2019-09-24 | Larry Zhang | President | A | — | — |
| 2019-08-20 | Wei-Wu He | Chief Executive Officer | Buy | — | — |
| 2019-08-15 | Wei-Wu He | Chief Executive Officer | Buy | — | — |
| 2019-06-21 | Ken Keyong Ren | Director | A | — | — |
| 2019-06-21 | Wei-Wu He | CEO | A | — | — |
| 2019-06-21 | James Huang | Director | A | — | — |
| 2019-06-21 | RAJESH C MD SHROTRIYA | Director | A | — | — |
| 2019-06-21 | Franklin Cary Salisbury jr | Director | A | — | — |
| 2019-06-21 | Yue Alexander Wu | Director | A | — | — |
| 2019-06-21 | Quan Zhou | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 1,019,852 | — |
| — | 10%+ Owner | 1,004,767 | — |
| — | 10%+ Owner | 977,338 | — |
| — | 10%+ Owner | 973,376 | — |
| — | 10%+ Owner | 908,789 | — |
| — | Chairman and CEO | 894,553 | — |
| — | 10%+ Owner | 849,876 | — |
| — | Director | 371,708 | — |
| — | COO, Gen Counsel & Secretary | 10,776 | — |
| — | VP Fin & Principal Account Off | 3,500 | — |
| — | President | 2,015 | — |
| — | CEO and Director | 754 | — |
| — | Chief Executive Officer | 754 | — |
| — | Chief Financial Officer | 600 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CASI quote page; the site-wide leaderboard is on the insider transactions hub.